Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin for Functional Impairment Related to Psychiatric Symptoms
NCT06442423Phase 1Recruiting
- Sponsor
- Yale University
- Start
- Oct 2024
- Primary completion
- Dec 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of psilocybin in major depressive disorder (MDD), anxiety disorder, post-traumatic stress disorder (PTSD) and 2 more, sponsored by Yale University. Primary endpoints: Columbia-Suicide Severity Rating Scale at 6 weeks and Adverse Events Log at 6 weeks. Started Oct 2024; status: recruiting.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)anxiety disorderpost-traumatic stress disorder (PTSD)substance use disorder (SUD)obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NCT06442423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06442423.